Clinical Trial: Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional




Official Title: OPuS-4: An Open-label Study to Evaluate the Long-term Safety of Avoralstat in Subjects With Hereditary Angioedema

Brief Summary: This is an open-label study designed to evaluate the long-term safety of prophylactic avoralstat (500 mg three times daily) when given to approximately 150 patients with hereditary angioedema (HAE) for a duration of up to 72 weeks. The study will also evaluate the long-term efficacy and impact on quality of life of avoralstat prophylactic treatment.